It can be hard for drug makers to pull the plug on a drug in development, even when all signs indicate they should – resulting in many drugs getting past the preclinical floodgates, only to fail. The mistake: Not having a clinical strategy from the get-go.

A smart, defined clinical strategy sets objective expectations at the beginning of a drug’s development for when and on what criteria development will be terminated. This forces drug developers to ask, “Why are we creating this drug in the first place?”

The answer—and the true drug development opportunity—lies in an understanding of the best available science and patient target(s) for the drug.

Before you take your drug to the point of no return, learn more about TD2’s insight from president and CEO, Stephen Gately, on how to be more strategic from the start in Applied Clinical Trials.

Efficient Data Management: One Way to Expedite the Clinical Development Proces

Debates on the safety and effectiveness of vaccines have captured the public’s attention recently. A vaccine is a preventative strategy for certain...

Read more +

The Clinical Trial Process Continues Amid COVID-19

It’s no secret that the top health concern on most Americans’ minds today is COVID-19 – a unprecedented disrupter like we’ve never seen...

Read more +

Technology Challenges and Trends in Clinical Trials

Cancer remains a leading cause of death among Americans with nearly two million newly diagnosed patients in 2018. As this trend continues, various...

Read more +

GET STARTED

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.